There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Adamas Pharmaceuticals (ADMS), Epizyme (EPZM) and Conatus Pharmaceuticals (CNAT) with bullish sentiments.
Adamas Pharmaceuticals (ADMS)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Adamas Pharmaceuticals, with a price target of $40. The company’s shares closed on Friday at $11.89, close to its 52-week low of $11.70.
Selvaraju said:
“Valuation methodology, risks and uncertainties. Our valuation ascribes a $1.15B valuation to GOCOVRI in PD $400M value for ADS-5102 based on a risk-adjusted net present value (rNPV) that employs a 15% discount rate, 30% effective tax rate and 30% cost of sales and marketing. We utilize a 60% probability of success for ADS-5102.”
According to TipRanks.com, Selvaraju is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -8.0% and a 31.7% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, Synergy Pharmaceuticals Inc, and Bausch Health Companies Inc.
Adamas Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $29.50, a 148.1% upside from current levels. In a report issued on November 1, Cowen & Co. also maintained a Buy rating on the stock with a $30 price target.
.
See today’s analyst top recommended stocks >>
Epizyme (EPZM)
H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Epizyme today and set a price target of $25. The company’s shares closed on Friday at $7.89, close to its 52-week low of $7.61.
Fein commented:
“Our price target of $25 for EPZM is based on a probability-adjusted sum-of-parts NPV-DCF: $2.9 (Taz, DLBCL, EZH2mut) + $16.0 (Taz, FL, EZH2mut) + $1.3 (Taz, INI- solid tumor) + $0.9 (DOT1L inhibitor) + $3.7 (cash). Risks to our investment thesis and target price include: (1) failure in clinical trials; (2) failure to secure regulatory approvals; and (3) a smaller-than-anticipated commercial opportunity due to market sizing, competition, and pricing. Epizyme, Inc.”
According to TipRanks.com, Fein is a 5-star analyst with an average return of 13.0% and a 46.1% success rate. Fein covers the Healthcare sector, focusing on stocks such as Proteostasis Therapeutics Inc, ACADIA Pharmaceuticals Inc, and Strongbridge Biopharma Plc.
Currently, the analyst consensus on Epizyme is a Strong Buy with an average price target of $21.14, which is a 167.9% upside from current levels. In a report issued on October 22, Roth Capital also maintained a Buy rating on the stock with a $18 price target.
.
Conatus Pharmaceuticals (CNAT)
H.C. Wainwright analyst Ed Arce maintained a Buy rating on Conatus Pharmaceuticals today and set a price target of $15. The company’s shares closed on Friday at $5.12.
Arce said:
“We continue to view the prospects for an unequivocal win as highly likely, and even more so after the company hosted its recent KOL Symposium on NASH cirrhosis and portal hypertension with leading experts Dr. and Dr. Jaime Bosch. We also expect positive results to represent a significant catalyst for the shares, not only immediately following the release, but also in the days and weeks following as investors revisit the name, realize its unique position within the greater NASH universe, and prepare potential positions ahead of readouts of ENCORE-NF (for NASH ENCORE-LF (for Liver Function), now expected in mid-2019, from 2H19 previously. Recall, ENCORE- PH is a Phase 2b study (NCT02960204) of emricasan (a pan-caspase inhibitor) in about 240 patients, across approximately 90 U.S.”
According to TipRanks.com, Arce is a 5-star analyst with an average return of 16.1% and a 40.5% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Melinta Therapeutics Inc, and Collegium Pharmaceutical.
Conatus Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $14, which is a 173.4% upside from current levels. In a report issued on November 1, Oppenheimer also assigned a Buy rating to the stock with a $14 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
